News
21.06.16
Preliminary results reporting the safety and effectiveness of gene therapy in patients with metachromatic leukodystrophy published in The Lancet
The gene therapy developed in the laboratories of the San Raffaele Telethon Institute for Gene Therapy in Milan (SR-Tiget) remains effective as a potential early treatment of metachromatic leukodystrophy (MLD).
30.05.16
Strimvelis receives European marketing authorisation to treat ADA-SCID
The European Commission has approved the first ex-vivo stem cell gene therapy to treat patients with a very rare disease of the immune system
16.06.14
Gene therapy: a "molecular scalpel" corrects the genes of blood stem cells
A group of researchers at the San Raffaele Telethon Institute for Gene Therapy (TIGET) in Milan was able for the first time to rewrite the DNA of human blood stem cells by editing the genome.
14.01.14
TIGEM: a centre of excellence for the south
The new premises of the Telethon Institute for Genetics and Medicine (Tigem) is set to open in the former "Olivetti area" in Pozzuoli.
09.07.13
The Hiv virus used to cure two severe genetic diseases
The AIDS virus can be used to treat two severe hereditary diseases.
24.10.12
Alliance between Fondazione Telethon and biopharmaceutical company Shire for research and development of new therapies for rare genetic diseases
Fondazione Telethon has signed an important agreement to collaborate with the international pharma company Shire plc.
18.10.10
A Tripartite Alliance to Cure Seven Genetic Diseases
Fondazione Telethon, Ospedale San Raffaele, and GlaxoSmithKline have entered into a strategic alliance to develop and make available innovative gene therapies for seven severe rare genetic diseases.
